Galapagos NV (Euronext: GLPG) announced today that the U.S. National
Institutes of Health (NIH) have extended their agreement with Galapagos’
service division BioFocus for the operation of the Molecular Libraries
Small Molecule Repository (MLSMR) through December 2012. According to the
terms of this agreement, Galapagos will be eligible to receive up to $8.6
million (EUR7.0 million) over the course of the two year extension.
BioFocus runs a compound management facility for a number of industrial
and U.S. government customers out of its Compound Focus, Inc. subsidiary
in South San Francisco. Home to the MLSMR since 2004, this facility
acquires and stores compounds under the NIH contract and distributes
these compounds for high-throughput biological screening throughout the
NIH’s academic network in the U.S.
“We are pleased that the NIH has exercised its option to extend its
long-standing collaboration with BioFocus’ compound management facility
for another two years. BioFocus has proven that it consistently delivers a
high-quality service across the vast NIH screening center network,” said
Onno van de Stolpe, CEO of Galapagos.
About the Molecular Libraries Small Molecule Repository (a Roadmap
The NIH MLSMR collects samples for high throughput biological screening
and distributes them to the NIH Molecular Libraries Screening Center
Network. MLSMR is a key component of the Molecular Libraries Initiative,
a NIH Roadmap project supporting ‘new pathways to discovery in the 21st
century’. The project is funded in whole with U.S. federal funds from the
National Institutes of Health, Department of Health and Human Services,
under contract HHS-N-278-2004- 41001C with Compound Focus, Inc.
BioFocusaims to expand its partners’ drug pipelines by accelerating the
gene-to-drug candidate discovery process. This is achieved through a
comprehensive discovery platform, which includes target discovery in human
primary cells, focused as well as diverse compound libraries, in vitro and
cell-based screening, structural biology, medicinal chemistry, ADME/PK
services, supported by unique chemogenomic and informatics tools, and
compound library acquisition, storage and distribution services. As a
service division of Galapagos, BioFocus has over 250 employees based in
the UK, the US and Switzerland. More info at: www.biofocus.com
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and
antibody therapies with novel modes-of-action. The Company is progressing
one of the largest pipelines in biotech, with four clinical and over 50
small molecule discovery/pre-clinical programs. Through
risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen
Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to
receive EUR3.3 billion in downstream milestones, plus royalties. Together
with its BioFocus and Argenta service operations, Galapagos has over 670
employees and operates facilities in six countries, with global
headquarters in Mechelen, Belgium. More info at: www.glpg.com
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
This release may contain forward-looking statements, including,
without limitation, statements containing the words “believes,”
“anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,”
“may,” “will,” “could,” “stands to,” and “continues,” as well as similar
expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause the
actual results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by
law or regulation.
is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein. All reproduction for further
distribution is prohibited.
Source: Galapagos NV via Thomson Reuters ONE
Copyright 2010, Market Wire, All rights reserved.